Monitor upcoming Phase 1 data for SEP-479 and SEP-204 in Q1 2027 as key catalysts. The revenue miss and wider loss may pressure the stock near-term, but the strong cash runway and pipeline milestones provide a longer-term focus.
Drugs in focus
SEPN drug pipeline →SEP-479
● Neutral Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- If Phase 1 data are positive, SEP-479 would still need to complete Phase 2 and Phase 3 trials before any potential FDA submission, placing a potential approval several years away (likely 2029-2031 at the earliest).
- Next catalyst
- None dated
What to watchThe next catalyst for SEP-479 is the Phase 1 topline safety, PK and PD data readout, guided for late 2026 or early 2027. Positive data would validate the oral small-molecule approach against an injectable standard of care (YORVIPATH) and could drive SEPN shares higher given the strong analyst consensus. Negative data (safety signals or poor PK/PD) would be a significant setback for Septerna's lead wholly-owned program.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $52.34entry
- T+1 · 6d ago −7.22%α −8.54% · $48.56
- T+4 · todayOpen
- T+5 · in 9h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Septerna reported Q3 2026 revenue of $18.9M (below consensus $20.8M) and a GAAP EPS loss of $0.57 (wider than the consensus loss of $0.40). The company highlighted pipeline progress for SEP-479 and SEP-204, with Phase 1 data expected in Q1 2027, and maintains a cash runway into mid-2029.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $18.9M vs consensus $20.8M and vs $21.5M in Q3 2025
- GAAP diluted EPS -$0.57 vs consensus -$0.40 and vs +$0.18 in Q3 2025
- Net loss $26.6M vs net income $8.2M in Q3 2025
- Cash position $565.2M, expected to fund operations into mid-2029
- Phase 1 data for SEP-479 (PTH1R agonist) expected Q1 2027
- SEP-204 (TSHR NAM) Phase 1 trial planned for Q1 2027
- Novo collaboration milestones achieved $13M to date
Financial Impact
Revenue miss of ~$1.9M (9% below consensus) and EPS miss of $0.17 (42.5% below consensus)
Risk Factors
- Revenue decline YoY and below consensus
- Wider net loss compared to prior year
- Clinical-stage biotech with no approved products; pipeline execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398924 |
Track record
25 reports on SEPN
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $41.67 −0.45% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Viewing Entry $52.34 Now $41.67 +20.39% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $41.67 +8.21% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $41.67 +13.39% ▲ +7.62% +8.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers